Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will add two new centers to its extensive network by furthering its partnership with the PLA Navy General Hospital ("Navy General Hospital" or "the hospital"), located in Beijing.

Concord Medical will add two new centers to the Beijing-based Navy General Hospital's existing facilities, bringing the total number of centers under the Company's management at the hospital to seven. One of the centers will house an Image Guided Radiation Therapy (IGRT) system and the other center will house a Body Gamma Knife system. The IGRT center commenced trial operation in mid June and both centers are expected to enter into full operation in the third quarter of 2010. Prior to these new centers, Concord Medical had been managing five radiotherapy and diagnostic imaging centers at the Navy General Hospital, one of Concord Medical's earliest hospital partners. With the additional centers, the hospital will further strengthen its position to become one of the top cancer treatment facilities in China.

"We are excited to further expand our services at the Navy General Hospital with the addition of two new centers. This expansion underscores our ability to grow with our hospital partners through quality service and effective management, and puts the Navy General Hospital into one of the top cancer treatment facilities in China. In addition, furthering a longstanding partnership symbolizes recognition of the value of our services on top of our financial support to the hospital," said Dr. Jianyu Yang, director, president and chief executive officer of Concord Medical. "Concord Medical is on track to achieve our goal of operating at least 200 centers by 2012. As the industry leader with the largest network of radiotherapy and diagnostic imaging centers in China, we are committed to making cancer treatment more readily available in China and are confident that we are well positioned to benefit from a favorable market environment supported by medical reform policies and increasing consumer demand for world-class cancer treatment."

Source:

Concord Medical Services Holdings Limited

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New protein platform enhances cancer immunotherapy